|
Q4 2019
|
20 |
379,352 |
TXG, AXSM, CNST, Biohaven Pharmaceuticals
|
13F-HR
|
2/13/2020 |
000095012320001878 |
|
Q3 2019
|
21 |
262,408 |
TXG, Biohaven Pharmaceuticals, ASND, SWAV
|
13F-HR
|
11/13/2019 |
000095012319010839 |
|
Q2 2019
|
21 |
317,188 |
ASND, SWAV, Biohaven Pharmaceuticals, OBSV
|
13F-HR
|
8/13/2019 |
000095012319007806 |
|
Q1 2019
|
21 |
341,753 |
ASND, Biohaven Pharmaceuticals, TCDA, SWAV
|
13F-HR
|
5/14/2019 |
000095012319004909 |
|
Q4 2018
|
19 |
232,951 |
Biohaven Pharmaceuticals, ASND, OBSV, BCRX
|
13F-HR
|
2/13/2019 |
000095012319001657 |
|
Q3 2018
|
21 |
374,474 |
ECYT, Biohaven Pharmaceuticals, OBSV, ASND
|
13F-HR
|
11/13/2018 |
000095012318011328 |
|
Q2 2018
|
18 |
334,079 |
ECYT, Biohaven Pharmaceuticals, OBSV, ASND
|
13F-HR
|
8/13/2018 |
000095012318008382 |
|
Q1 2018
|
17 |
414,401 |
AVXS, ECYT, ASND, Biohaven Pharmaceuticals
|
13F-HR
|
5/14/2018 |
000095012318005292 |
|
Q4 2017
|
18 |
417,194 |
AVXS, Biohaven Pharmaceuticals, ASND, ARGX
|
13F-HR
|
2/13/2018 |
000095012318001778 |
|
Q3 2017
|
21 |
361,938 |
AVXS, Biohaven Pharmaceuticals, ASND, ZGNX
|
13F-HR
|
11/13/2017 |
000095012317010386 |
|
Q2 2017
|
19 |
250,383 |
AVXS, Biohaven Pharmaceuticals, ASND, PDSB
|
13F-HR
|
8/11/2017 |
000095012317007498 |
|
Q1 2017
|
20 |
244,417 |
AVXS, BCRX, ASND, DBV.PA
|
13F-HR
|
5/12/2017 |
000095012317004811 |
|
Q4 2016
|
22 |
208,495 |
AVXS, BCRX, PDSB, DBV.PA
|
13F-HR
|
2/13/2017 |
000095012317001786 |
|
Q3 2016
|
24 |
194,834 |
AVXS, BCRX, PDSB, DBV.PA
|
13F-HR
|
11/14/2016 |
000095012316022460 |
|
Q2 2016
|
23 |
165,687 |
AVXS, PDSB, DBV.PA, BCRX
|
13F-HR
|
8/12/2016 |
000095012316019771 |
|
Q1 2016
|
22 |
152,014 |
AVXS, PDSB, ASND, BCRX
|
13F-HR
|
5/13/2016 |
000095012316017148 |
|
Q4 2015
|
15 |
121,744 |
PDSB, RGNX, DBV.PA, ASND
|
13F-HR
|
2/12/2016 |
000095012316014521 |